* H1 pretax profit 10.2 mln stg vs 8.2 mln stg
* H1 total revenue rises 2 pct
* Says confident on outlook for the rest of the year
* Maintains interim dividend
Dec 1 British inhaled-drug specialist
Consort Medical reported a higher first-half pretax
profit on strong volume growth at its Bespak unit's core
The company, which specialises in making asthma and
anaesthesia medical devices, said it expected full-year results
slightly ahead of expectations.
For the May-October period, Consort reported a pretax profit
before special items of 10.2 million pounds, compared with 8.2
million pounds a year ago.
Total revenue rose 2 percent to 71.1 million pounds. Revenue
at the company's Bespak division rose 17 percent to 47.9 million
With net debt rising 34 percent to 42.6 million pounds at
the end of the period, it kept interim dividend unchanged at 7
pence a share.
Consort shares closed at 498 pence on Wednesday on the
London Stock Exchange.